The director at AbbVie discussed the timeline for when a regulatory decision may come for migraine treatment atogepant, and whether additional trials are necessary.
Lawrence Severt, MD, PhD
Advertisement
Director, AbbVie
Articles by Lawrence Severt, MD, PhD
The director at AbbVie highlighted where atogepant stands among the increasing treatment landscape of anti-calcitonin gene-related peptide options within the migraine treatment landscape.
The director at AbbVie discussed a number of abstracts presented at AAN 2021 involving atogepant and its phase 3 ADVANCE study.
Advertisement
Latest Updated Articles
Advantages of Atogepant in Ever-Growing CGRP Market: Lawrence Severt, MD, PhDPublished: May 4th 2021 | Updated:
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Paraneoplastic Neurologic Syndromes Present Before Testicular Germ Cell Tumor Diagnosis, Study Shows
2
NeurologyLive® Brain Games: October 26, 2025
3
FDA Fast Tracks Etalanetug, Encouraging Interim TEMPO-4 Data, Initial Data on Cell Therapy UX-DA001
4
Benzodiazepines and Antipsychotics Tied to Higher Mortality in Hospice Patients With Dementia
5
